Dapagliflozin efficacy and safety: A perspective review

Therapeutic Advances in Drug Safety

Volumn 5, Issue 6, 2014, Pages 242-254

  Anderson, Sarah L ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

dapagliflozin; hypoglycemic agents; sodium glucose transporter 2; type 2 diabetes mellitus

Indexed keywords

DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

ABNORMAL LABORATORY RESULT; BLADDER CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FUNGAL GENITAL INFECTION; HUMAN; HYPOGLYCEMIA; HYPOTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RHINOPHARYNGITIS; URINARY TRACT INFECTION;

EID: 84911020493     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098614551938     Document Type: Review

References (41)

1. American Diabetes Association (2014) Standards of medical care in diabetes–2014. Diabetes Care 37(Suppl. 1): S14–S80.
2. AstraZeneca (2012) FORXIGA™ (dapagliflozin) now approved in European Union for treatment of type 2 diabetes. Available at: http://www.astrazeneca.com/Media/Press-releases/Article/20121114–forxiga-eu-approval-type-2-diabetes (accessed 8 July 2014).
3. AstraZeneca (2014a) Xigduo™ (dapagliflozin and metformin hydrochloride) approved in the European Union for type 2 diabetes. Available at: http://www.astrazeneca.com/Media/Press-releases/Article/20142101–xigduo-dapagliflozin-and-metformin-hydrochloride (accessed 8 July 2014).
4. AstraZeneca (2014b) U.S. FDA approves FarxigaTM (dapagliflozin) tablets for the treatment of adult patients with type 2 diabetes. Available at: http://www.astrazeneca-us.com/media/press-releases/Article/20140113-us-fda-approves-farxiga-tablets (accessed 8 July 2014).
5. Bailey C. Gross J. Pieters A. Bastien A. List J. (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375: 2223–2233.
6. Bailey C. Gross J. Yadav M. Iqbal N. Mansfield T. List J. (2011) Sustained efficacy of dapagliflozin when added to metformin in type 2 diabetes inadequately controlled by metformin monotherapy. Diabetalogia 54(Suppl. 1): A146.
7. Bailey C. Iqbal N. T–joen C. List J. (2012) Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab 14: 951–959.
8. Bristol-Myers Squibb Company (2014) Farxiga [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
9. Danaei G. Finucane M. Lu Y. Singh G. Cowan M. Paciorek C. (2011) National, regional and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378: 31–40.
10. Defronzo R. Hompesch M. Kasichayanula S. (2013) Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 36: 3169–3176.
11. Del Prato S. Nauck M. Rohwedder K. Thuerkauf A. Langkilde A. Parikh S. (2011) Long-term efficacy and safety of add-on dapagliflozin vs add-on glipizide in patients with type 2 diabetes mellitus inadequately controlled with metformin: 2-year results. Diabetalogia 54(Suppl. 1): A852.
12. Ferrannini E. Ramos S. Salsali A. Tang W. List J. (2010) Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise. Diabetes Care 33: 2217–2224.
13. Fowler M. (2011) Pitfalls in outpatient diabetes management and inpatient glycemic control. Clinical Diabetes 29: 79–85.
14. Geerlings S. (2008) Urinary tract infections in patients with diabetes mellitus: epidemiology, pathogenesis and treatment. Int J Antimicrob Agents 31(Suppl. 1): S54–S57.
15. Henry R. Murray A. Marmolejo M. Hennicken D. Ptaszynska A. List J. (2012) Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 66: 446–456.
16. Inzucchi S. Bergenstal R. Buse J. Diamant M. Ferrannini E. Nauck M. (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55: 1577–1596.
17. Jabbour S. Hardy E. Sugg J. Parikh S., Study 10 Group (2014) Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week multicenter, randomized, double-blind placebo-controlled study. Diabetes Care 37: 740–750.
18. Johnsson K. Ptaszynska A. Schmitz B. Sugg J. Parikh S. List J. (2013a) Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 27: 473–478.
19. Johnsson K. Ptaszynska A. Schmitz B. Sugg J. Parikh S. List J. (2013b) Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 27: 479–484.
20. Kaku K. Inoue S. Matsuoka O. Kiyosue A. Azuma H. Hayashi N. (2013) Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 15: 432–440.
21. Kasichayanula S. Chang M. Hasegawa M. Liu X. Yamahira N. LaCreta F. (2011a) Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab 13: 357–365.
22. Kasichayanula S. Liu X. Pe Benito M. Yao M. Pfister M. LaCreta F. (2013) The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol 76: 432–444.
23. Kasichayanula S. Liu X. Shyu W. (2011b) Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab 13: 47–54.
24. Kohan D. Fioretto P. Tan W. List J. (2014) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85: 962–971.
25. Komoroski B. Vachharajani N. Boulton D. Kornhauser D. Geraldes M. Li L. (2009) Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 85: 520–526.
26. List J. Woo V. Morales E. Tang W. Fiedorek F. (2009) Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32: 650–657.
27. Mathers C. Loncar D. (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3: e442.
28. Nauck M. Del Prato S. Meier J. Duran-Garcia S. Rohwedder K. Elze M. (2011) Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin. Diabetes Care 34: 2015–2022.
29. Rosenstock J. Vico M. Wei L. Salsali A. List J. (2012) Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 35: 1473–1478.
30. Stark Casagrande S. Fradkin J. Saydah S. Rust K. Cowie C. (2013) The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care 36: 2271–2279.
31. Strojek K. Yoon K. Hruba V. Elze M. Langkilde A. Parikh S. (2011) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 13: 928–938.
32. UK Prospective Diabetes Study (1995) Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 310: 83–88.
33. UK Prospective Diabetes Study (1995) Overview of 6 years– therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study (UKPDS) Group. Diabetes 44: 1249–1258.
34. van den Heuvel L. Assink K. Willemsen M. Monnens L. (2002) Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 111: 544–547.
35. Weber M. Mansfield T. Alessi F. Ptaszynska A. (2013a) Effects of dapagliflozin on blood pressure in diabetic patients with hypertension inadequately controlled by a renin–angiotensin system blocker. Presented at the Annual Meeting of the American Heart Association (AHA); 16–20 November 2013; Dallas, TX. Poster 2095.
36. Weber M. Mansfield T. T–joen C. (2013b) Dapagliflozin for reduction of blood pressure in diabetic patients inadequately controlled with combination antihypertensive regimen. Presented at the Annual Meeting of the American Heart Association (AHA); 16–20 November 2013; Dallas, TX. Poster 2097.
37. Wilding J. Norwood P. T–joen C. Bastien A. List J. Fiedorek F. (2009) A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers. Diabetes Care 32: 1656–1662.
38. Wilding J. Woo V. Rohwedder K. Sugg J. Parikh S. for the Dapagliflozin 006 Study Group (2014) Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 16: 124–136.
39. Wright E. (2001) Renal Na+-glucose cotransporters. Am J Physiol Renal Physiol 280: F10–F18.
40. Wright E. Turk E. (2004) The sodium/glucose cotransport family SLC5. Eur J Physiol 447: 510–518.
41. Zhang L. Feng Y. List J. Kasichayanula S. Pfister M. (2010) Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 12: 510–516.